Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rheumatoid Arthritis
Biotech
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
Phase 2 data on Spyre’s anti-TL1A antibody fell short of expectations, prompting the biotech to deprioritize monotherapy work in the indication.
Nick Paul Taylor
Aug 26, 2026 5:40am
Scipher picks up Chemomab’s liver disease drug via merger
Jul 8, 2026 9:26am
Cullinan's new data makes clearest case yet for autoimmune TCEs
Jun 6, 2026 5:15am
Gilead scraps lead arthritis drug from $405M MiroBio buyout
May 29, 2026 7:18am
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
May 7, 2026 11:15am
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
Apr 29, 2026 8:38am
